While as a monoclonal therapy CC40.8 did not reduce upper airway viral loads significantly, a S2 directed antibody response including IgA isotype antibodies, such as those elicited by SARS-CoV-2 vaccination or infection, may prove more effective at reducing upper airway viral loads and transmission risk. Here, CD79A is linked to infection.